Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333148 | 0.91 | SIRT2 (0.47) | SIRT2SIRT1ALDH1A1KDM4EMAPT | |
| SCHEMBL2330847 | 0.89 | SIRT2 (0.50) | SIRT2SIRT1ALDH1A1GAAESR1 | |
| SCHEMBL2331148 | 0.88 | PTGS2 (0.44) | SIRT2SIRT1ALDH1A1KDM4EGAA | |
| SCHEMBL2331360 | 0.86 | SIRT2 (0.43) | SIRT2SIRT1MAPTPTGS2NR1H2 | |
| SCHEMBL2326870 | 0.84 | SIRT2 (0.44) | SIRT2SIRT1ALDH1A1GAAESR1 | |
| SCHEMBL2329102 | 0.83 | SIRT2 (0.46) | SIRT2SIRT1ALDH1A1HPGDHDAC1 | |
| SCHEMBL2323585 | 0.79 | PTPN2 (0.59) | ALDH1A1KDM4EMAPTGAAGLA | |
| SCHEMBL2330571 | 0.78 | SIRT2 (0.52) | SIRT2SIRT1ALDH1A1KDM4EGAA | |
| SCHEMBL4588945 | 0.77 | NR1H2 (0.43) | SIRT2SIRT1ESR1ESR2PTGER4 | |
| SCHEMBL1104831 | 0.76 | NLRP3 (0.61) | SIRT2SIRT1ALDH1A1KDM4EESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246808-B1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | BAYER SCHERING PHARMA AG (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7345075-B2 | 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7329679-B2 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7115645-B2 | 1,2 diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1246808-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | disclosed |
| WO-2001051473-A1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | CYP2E1, CYP1B1, CYP1A1 | SIRT2 1457/4885SIRT1 1514/4885ALDH1A1 29/4885 |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | SIRT2 739/4885SIRT1 1022/4885ALDH1A1 118/4885 |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | SIRT2 739/4885SIRT1 1022/4885ALDH1A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.